CA2264718A1 - Coprecipites solides augmentant la biodisponibilite de substances lipophiles - Google Patents

Coprecipites solides augmentant la biodisponibilite de substances lipophiles

Info

Publication number
CA2264718A1
CA2264718A1 CA002264718A CA2264718A CA2264718A1 CA 2264718 A1 CA2264718 A1 CA 2264718A1 CA 002264718 A CA002264718 A CA 002264718A CA 2264718 A CA2264718 A CA 2264718A CA 2264718 A1 CA2264718 A1 CA 2264718A1
Authority
CA
Canada
Prior art keywords
coprecipitates
solid
lipophilic substances
enhanced bioavailability
tpgs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002264718A
Other languages
English (en)
Other versions
CA2264718C (fr
Inventor
Shimon Amselem
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmos Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL11917696A external-priority patent/IL119176A/en
Priority claimed from US08/833,076 external-priority patent/US5891469A/en
Application filed by Individual filed Critical Individual
Publication of CA2264718A1 publication Critical patent/CA2264718A1/fr
Application granted granted Critical
Publication of CA2264718C publication Critical patent/CA2264718C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
CA002264718A 1996-09-01 1997-08-27 Coprecipites solides augmentant la biodisponibilite de substances lipophiles Expired - Fee Related CA2264718C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IL11917696A IL119176A (en) 1996-09-01 1996-09-01 Soluble coprecipitates for enhanced oral bioavailability of lipophilic substances
IL119176 1996-09-01
US08/833,076 US5891469A (en) 1997-04-02 1997-04-02 Solid Coprecipitates for enhanced bioavailability of lipophilic substances
US08/833,076 1997-04-02
PCT/US1997/015072 WO1998008490A1 (fr) 1996-09-01 1997-08-27 Coprecipites solides augmentant la biodisponibilite de substances lipophiles

Publications (2)

Publication Number Publication Date
CA2264718A1 true CA2264718A1 (fr) 1998-03-05
CA2264718C CA2264718C (fr) 2006-05-30

Family

ID=26323300

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002264718A Expired - Fee Related CA2264718C (fr) 1996-09-01 1997-08-27 Coprecipites solides augmentant la biodisponibilite de substances lipophiles

Country Status (5)

Country Link
EP (1) EP1017366A4 (fr)
JP (1) JP2001523221A (fr)
AU (1) AU730216B2 (fr)
CA (1) CA2264718C (fr)
WO (1) WO1998008490A1 (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891845A (en) * 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
IT1298731B1 (it) * 1998-03-13 2000-02-02 Recordati Chem Pharm Composizioni farmaceutiche contenenti complessi di inclusione con melatonina
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US6200550B1 (en) * 1998-12-11 2001-03-13 Q-Pharma, Inc. Oral care compositions comprising coenzyme Q10
US20080070981A1 (en) 2000-02-23 2008-03-20 Henryk Borowy-Borowski Water-soluble compositions of bioactive lipophilic compounds
US6045826A (en) 1999-04-02 2000-04-04 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US6632443B2 (en) * 2000-02-23 2003-10-14 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
AR025587A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
EP1246668B1 (fr) * 1999-12-01 2005-11-30 Natco Pharma Limited Composition pharmaceutique lyophilisee a action rapide s'administrant par voie orale utilisee pour traiter la migraine
AU2001225432A1 (en) * 2000-01-20 2001-07-31 Supratek Pharma, Inc. Novel podophyllotoxin compositions
DE10046541A1 (de) 2000-09-19 2002-03-28 Knoll Ag Mechanisch stabile darreichungsformen, enthaltend Ubichinone
AR033711A1 (es) * 2001-05-09 2004-01-07 Novartis Ag Composiciones farmaceuticas
NZ531944A (en) 2001-10-19 2006-03-31 Isotechnika Inc Synthesis of cyclosporin analogs
FR2840614B1 (fr) * 2002-06-07 2004-08-27 Flamel Tech Sa Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
AU2002350719A1 (en) 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
EP1592760A4 (fr) 2003-01-31 2009-08-12 Smithkline Beecham Corp Compositions solides de dispersion
CA2516448A1 (fr) * 2003-02-19 2004-09-02 H. Lundbeck A/S Procede de preparation d'un agglomere par agglomeration a chaud
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
KR20060113950A (ko) * 2003-12-18 2006-11-03 디에스엠 아이피 어셋츠 비.브이. 비타민 ｅ의 용도
CA2578356C (fr) * 2004-09-24 2013-05-28 Boehringer Ingelheim Pharmaceuticals, Inc. Une nouvelle classe de matiere de type surfactant
CN101031284A (zh) * 2004-09-30 2007-09-05 伊斯曼化学公司 使亲脂性药物增溶而无显著外排抑制作用的含有维生素e tpgs分子的药物制剂和该制剂的用途
US20060088591A1 (en) * 2004-10-22 2006-04-27 Jinghua Yuan Tablets from a poorly compressible substance
US7446096B2 (en) * 2005-12-19 2008-11-04 Industrial Technology Research Institute Glutathione based delivery system
US8067380B2 (en) 2005-12-19 2011-11-29 Industrial Technology Research Institute Glutathione-based delivery system
WO2008007728A1 (fr) * 2006-07-13 2008-01-17 Kaneka Corporation Préparation orale contenue dans une structure à membrane lipidique, et agent contre la fatigue comprenant une coenzyme comme ingrédient actif
PE20081506A1 (es) 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
CA2718255C (fr) * 2008-03-11 2016-08-23 Aska Pharmaceutical Co., Ltd. Dispersion solide, compositions pharmaceutiques comprenant celle-ci, et procedes de production associes
WO2009117152A1 (fr) 2008-03-20 2009-09-24 Virun, Inc. Émulsions comprenant un dérivé de peg de tocophérol
US8765661B2 (en) 2008-03-20 2014-07-01 Virun, Inc. Compositions containing non-polar compounds
AR075180A1 (es) * 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
WO2010092925A1 (fr) * 2009-02-12 2010-08-19 あすか製薬株式会社 Dispersion solide, composition pharmaceutique comprenant celle-ci et procédés de production de la dispersion solide et de la composition pharmaceutique
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
CN103037708B (zh) 2010-03-23 2015-05-20 维尔恩公司 含有蔗糖脂肪酸酯的纳米乳液
US8741373B2 (en) 2010-06-21 2014-06-03 Virun, Inc. Compositions containing non-polar compounds
ITMI20112042A1 (it) * 2011-11-10 2013-05-11 Eratech S R L Polvere da ricostituire prima dell'uso comprendente melatonina e preparazione iniettabile ottenibile da tale polvere.
ITRM20120331A1 (it) 2012-07-12 2014-01-13 Guidotti & C Spa Labor Composizioni pediatriche orali liquide contenenti nepadutant.
FR2999081B1 (fr) * 2012-12-06 2015-02-27 Hra Pharma Lab Dispersion solide d'un modulateur selectif du recepteur a la progesterone
US9351517B2 (en) 2013-03-15 2016-05-31 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and compositions containing same
US9693574B2 (en) 2013-08-08 2017-07-04 Virun, Inc. Compositions containing water-soluble derivatives of vitamin E mixtures and modified food starch
HUP1300647A2 (hu) * 2013-11-12 2015-05-28 Druggability Technologies Ip Holdco Jersey Ltd Ciklosporin A és származékainak komplexei, elõállításuk és gyógyszerészeti kompozícióik
US11911361B2 (en) 2014-05-29 2024-02-27 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
US11331279B2 (en) 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
GB201410869D0 (en) * 2014-06-18 2014-07-30 Perioc Ltd Novel pharmaceutical formulations and their use in the treatment of periodontal disease
US9861611B2 (en) 2014-09-18 2018-01-09 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same
US10016363B2 (en) 2014-09-18 2018-07-10 Virun, Inc. Pre-spray emulsions and powders containing non-polar compounds
WO2016191651A1 (fr) * 2015-05-28 2016-12-01 Insys Development Company, Inc. Formulations de cannabinoïdes stables
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
BR112019013743A2 (pt) 2017-01-03 2020-01-21 Receptor Holdings Inc compostos medicinais e suplementos nutricionais
EP3582755A4 (fr) * 2017-02-15 2020-12-23 Molecular Infusions, LLC Préparations
CN108245683B (zh) * 2018-01-26 2020-02-14 华中科技大学 一种具有p-糖蛋白抑制功能的抗肿瘤前药及制备方法
TW202128158A (zh) * 2019-12-20 2021-08-01 瑞士商愛杜西亞製藥有限公司 包含n-[1-(5-氰基-吡啶-2-基甲基)-1h-吡唑-3-基]-2-[4-(1-三氟甲基-環丙基)-苯基]-乙醯胺之醫藥組合物
US20230070369A1 (en) * 2019-12-20 2023-03-09 Intervet Inc. Pyrazole pharmaceutical composition
EP4121057A1 (fr) * 2020-03-19 2023-01-25 AC Immune SA Traitements par dose des tauopathies
IT202200002528A1 (it) * 2022-02-11 2023-08-11 Pierpaoli Exelyas S R L Composizione comprendente melatonina ad alta biodisponibilità

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3102078A (en) * 1961-01-13 1963-08-27 Eastman Kodak Co Water-dispersible vitamin preparations
US3673163A (en) * 1970-06-16 1972-06-27 Lilly Co Eli Pharmacological preparation containing an acronycine-polyvinylprrolidone coprecipitate
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
US4327080A (en) * 1981-07-13 1982-04-27 E. R. Squibb & Sons, Inc. Novel Bendroflumethiazide formulations and method
US4758427A (en) * 1985-08-08 1988-07-19 Ciba-Geigy Corporation Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone
US5179122A (en) * 1991-02-11 1993-01-12 Eastman Kodak Company Nutritional supplement containing vitamin e
US5234696A (en) * 1991-12-27 1993-08-10 Abbott Laboratories Method of producing tablets, tablets produced thereby, and method of treatment using same
IT1255792B (it) * 1992-08-05 1995-11-16 Bayer Italia Spa Composizioni farmaceutiche per la somministrazione orale di diidropiridine in forma di bevanda
US5430021A (en) * 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
HU215966B (hu) * 1994-11-21 1999-07-28 BIOGAL Gyógyszergyár Rt. Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum
EP0825849A1 (fr) * 1995-05-19 1998-03-04 Abbott Laboratories Formulations auto-emulsifiantes de medicaments lipophiles
MY126358A (en) * 1996-03-22 2006-09-29 Glaxo Group Ltd Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs

Also Published As

Publication number Publication date
EP1017366A4 (fr) 2006-03-22
EP1017366A1 (fr) 2000-07-12
WO1998008490A1 (fr) 1998-03-05
JP2001523221A (ja) 2001-11-20
CA2264718C (fr) 2006-05-30
AU4237397A (en) 1998-03-19
AU730216B2 (en) 2001-03-01

Similar Documents

Publication Publication Date Title
CA2264718A1 (fr) Coprecipites solides augmentant la biodisponibilite de substances lipophiles
CA2294337A1 (fr) Preparation de compositions pharmaceutiques
ES2210554T3 (es) Composicion farmaceutica que comprende coenzima q 10.
CA2258095A1 (fr) Compositions contenant de la tetrahydrolipstatine
CA2227887A1 (fr) Compositions pharmaceutiques d'oestrogenes conjugues et leurs procedes d'utilisation
AR032073A1 (es) Las nanoparticulas lipidas anfifilicas para la incorporacion de los peptidos y/o las proteinas
KR20010008804A (ko) 카르두스 마리아누스 추출물 또는 이로부터 정제된 실리빈을함유하는 경구용 마이크로에멀젼 조성물
IE871584L (en) Sustained release capsule.
AU2433997A (en) Solid lipid compositions of lipophilic compounds for enhanced oral bioavailability
AU7854791A (en) Cationic lipids for intracellular delivery of biologically active molecules
IL114596A (en) Pharmaceutical compositions containing an active substance blended with a carrier process for preparation thereof and their use for preparation of inhalated drugs
CA2389235A1 (fr) Formulations d'hydrocodone a liberation lente
CA2058428A1 (fr) Formulations analgesiques
NZ231281A (en) Sustained release pharmaceutical preparations comprising the active agent dispersed in a solid matrix of a fatty acid ester of a polyglycerol
IL117889A0 (en) Pharmaceutical compositions containing lipophilic compounds
CA2326198A1 (fr) Formulations de cosolvants
IT1263840B (it) Formulazioni orali di ubidecarenone in forma di capsule
CA2216277A1 (fr) Compositions pharmaceutiques a liberation controlee, administrees par voie orale, contenant de la nifedipine comme principe actif
KR970706004A (ko) 호르몬 약물 및 에스트로겐 결핍을 치유하기 위한 그의 용도(novel hormonal medicaments and use thereof for correcting oestrogen deficiencies)
WO2003018064A3 (fr) Compositions de medicaments lipophiles
CA2356306A1 (fr) Phosphatidylinositols sulfates, leur preparation et utilisation
WO2004073592A3 (fr) Formulations semi-solides a liberation immediate pour l'administration de medicaments par voie orale
KR100352089B1 (ko) 페노피브레이트를 함유하는 경구용 마이크로에멀젼 조성물
ATE212840T1 (de) Oral anzuwendende feste arzneizubereitungen mit modulierter wirkstoffabgabe enthaltend nicorandil und verfahren zu deren herstellung
AU2127400A (en) A pharmaceutical composition for the administration of water-insoluble pharmaceutically active substances and process for preparation thereof

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKLA Lapsed

Effective date: 20090827